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Summary In the adoptive immunotherapy for cancer, the amounts of induced effector cells play a major role
in improving therapeutic efficacy. We have already demonstrated that interleukin 4 (IL-4) augments
proliferation of tumour-infiltrating lymphocytes (TILs) without altering the cytotoxic activity against
autologous tumour cells. The present study is designed to investigate how IL-4 augments TILs by using
established TIL clones in terms of IL-2/IL-2 receptor system. CD4+, CD8+ and CD4+CD8+ (double positive)
TIL clones were established from cancer patients. At clonal level, IL-4 augmented the proliferation of IL-2-
activated TIL clones irrespective of phenotypes. In order to clarify the mechanism of IL-4 at clonal level, the
blocking assay by anti-IL-2 receptor a and P chain and binding assay of IL-2 on the cell surface and the
measurement of the internalisation of IL-2 in the cell were performed. It was clarified that IL-4 up-regulated
the IL-2 receptor and then augmented the action of IL-2 molecule on the cell surface stimulated by IL-4.
Furthermore, binding IL-2 internalised rapidly into the cells. Thus, it is suggested that signal transduction is
augmented and proliferation of TILs is enhanced by IL-4 via the action of IL-2/IL-2 receptor system.
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Adoptive immunotherapy (AIT) using tumour-infiltrating
lymphocytes (TILs) has been carried out by various
investigators (Rosenberg et al., 1986; Topalian et al., 1988;
Yamaue et al., 1990). The number of transferred TILs is a
critical factor for obtaining a therapeutic effect. Interleukin 4
(IL-4) is a pleiotrophic cytokine that acts on various cell
types (Paul and O'Hara, 1987; Swain et al., 1988; Spits et al.,
1987; Horohov et al., 1988; Mitchell et al., 1989), and is
produced by helper T cell type 2 (Mosmann et al., 1986). It
has been reported that IL-4 mainly acts on B cells (BCGF, B-
cell growth factor) (Howard et al., 1982), and that it can
augment the cytotoxic activity of lymphokine-activated killer
(LAK) cells in a murine model (Mule et al., 1987). Recently,
it has been demonstrated that IL-4 inhibited LAK activity in
humans (Nagler et al., 1988). However, it has been reported
that IL-4 enhanced the proliferation of TILs obtained from
different types of human tumours (Kawakami et al., 1988,
1993). We have previously demonstrated that IL-4 augments
the proliferation of interleukin 2 (IL-2)-activated TILs
without inhibiting their cytotoxic activity against autologous
tumour cells. Thus, the combination of IL-2 with IL-4 may
lead to improved therapeutic efficacy of AIT using TILs
(Tsunoda et al., 1992a). However, the mechanism of IL-4 on
the augmentation of proliferation about TILs has not been
clarified yet. In the present study, we demonstrated that the
functional mechanism of IL-4 was clarified under clonal level.
Materials and methods
Culture media and tumour cell lines
Recombinant human IL-2 (Shionogi Pharmaceutical Co.,
Japan) and recombinant human IL-4 (Ono Pharmaceutical
Co., Japan) were used for cell stimulation. RPMI-1640
medium (Gibco, Grand Island, NY, USA) was supplemen-
ted with 10% heat-inactivated human AB serum obtained
from healthy subjects, 100 U ml-' penicillin, 100 pg ml -
streptomycin, 2.5 pg ml-1 amphotericin B, 2 mmol 1-1
glutamine and 25 mmol 1-l Hepes (complete medium).
Separation of TILs and autologous tumour cells
TILs were separated as previously described (Yamaue et al.,
1990; Tsunoda et al., 1992b). In brief, malignant fluids were
obtained from cancer patients and centrifuged. The cell
pellets were washed twice and resuspended with complete
medium. Cells were then layered onto Ficoll -Hypaque
gradients and centrifuged at 400 g for 30 min at 20'C. The
interface fraction was collected, washed and resuspended in
complete medium, and layered onto discontinuous gradients
of 70% and 100% Ficoll-Hypaque. After centrifugation at
400 g for 30 min, the TILs were concentrated at the 100%
interface, and the tumour cells were concentrated at the 70%
interface. The purity of lymphocytes in the TIL-rich fraction
was 60-85%, and this fraction was used as the source of
TILs. The tumour cell-rich fraction was contaminated by
mesothelial cells and mononuclear cells. To eliminate these
cells, the fraction was layered onto discontinuous gradients
composed of 4 ml each of 20%, 15% and 10% Percoll
(Pharmacia) in complete medium in 15 ml plastic tubes, and
then centrifuged at 25 g for 7 min at 20°C. Tumour cells
depleted of lymphocytes were collected from the bottom of
each tube, washed and resuspended in complete medium. The
purity of the tumour cells was usually more than 90% after
this extra centrifugation procedure. Freshly isolated tumour
cells were over 95% viable according to the trypan blue dye
exclusion test, and only cell fractions having less than 10%
contamination by non-malignant cells were accepted for use.
Cloning method
TIL clones were established by limiting dilution method
(Iwahashi et al., 1993). Briefly, maintained phase TILs were
seeded in 96-well U-bottom plates at 0.7 cells per well in
0.2 ml of complete medium containing 105 allogenic
peripheral blood mononuclear feeder cells which were
treated with 50 pg ml-' Mitomycin C (Kyowa Hakko,
Japan) for 30 min at 370C. IL-2 (1500 U ml-') and optimal
IL-4 (250 pg ml-' or 2.5 ng ml-') were used for stimulation
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from our previous data (Tsunoda et al., 1992). Every 4 days,
microcultures were supplemented with IL-2 and IL-4. After
16-24 days of culture, microcultures were scored micro-
scopically for growth. Grown microcultures were considered
as clones. Clonal microcultures were then split into several
microwells, expanded and analysed for surface marker
expression and functional properties.
DNA synthesis
TIL clones were cultured in triplicate in round-bottomed
microtitre plates with 1500 IU ml-' IL-2 and/or IL-4
(250 ig ml-' or 2.5 ng ml-') at 37°C. After 80 h, 1 ,uCi of
[3H]thymidine [3H]TdR, New England Nuclear, Boston,
USA) was added to each well and culture was continued
for an additional 16 h. Samples were harvested using a cell
harvester (Cambridge Technology, Cambridge, MA, USA)
and the amount of incorporated radioactivity was measured
using a liquid-scintillation counter.
IL-2 receptor blocking assay
Anti-CD25 antibody (anti-IL-2 receptor a chain, 10 Mug ml-',
CosmoBio, Tokyo, Japan) and TU27 (anti-IL-2 receptor ,B
chain, 50 jug ml-', kindly provided by Dr Sugamura, Tohoku
University, Japan) were used for IL-2 receptor blocking assay
(Yagita et al., 1989). The concentrations used have been
sufficiently proved for inhibition in the proliferation of T cells
by preliminary studies. Inhibition of DNA synthesis was used
to measure receptor blocking.
IL-2 binding assay and Scatchard analysis
IL-2 binding assay was performed by modified Robb's
method as previously described (Robb et al., 1984). In
brief, cells were washed three times in complete medium and
incubated for 6 h at 37°C to remove IL-2. After an additional
wash, the cells were resuspended in the same medium.
Binding of [1251I]IL-2 (Amersham, 600 Ci mmol-1) was
performed in triplicate in 100 jl containing 4-6 x 106 cells.
The incubation was performed for 90 min at 4°C. For every
time point non-specific binding was determined with a 100-
fold excess of cold IL-2. The specific binding represents the
difference between the total and non-specific binding.
Determination of the internalisation ofIL-2
Cells (2 x 106) were incubated with 200 pM ['251]IL-2 in
RPMI-Hepes at 4°C on ice for 30 min. They were then
washed three times, resuspendend in 1.0 ml RPMI-Hepes,
and incubated at 37°C for the indicated times. The
suspension was centrifuged, and the cell pellet was then
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treated for 10 min at 4°C with chilled 0.2 M glycin-HCl
buffer (pH 2.8). The radioactivity of the non-acid-eluted
fraction was then counted with a gamma counter and taken
to represent the labelled IL-2 internalised by clones (Fujii et
al., 1986; Yoshimoto et al., 1990).
Results
Characteristics of TIL clones
Thirty-five TIL clones incubated with IL-2 (1500 IU ml-')
and IL-4 (250 pg ml-') were established from seven cancer
patients. All TIL clones were CD3+ and TCRa/#f. Of these,
19 were CD4+ (54.3%), six were CD8+ (17.1%) and ten were
CD4+CD8+ (double positive) (Figure 1).
IL-4 augmented the proliferation of TIL clones
As shown in Table I, IL-4 alone augmented DNA synthesis
ofTIL clones, and moreover, IL-4 enhanced the proliferation
of IL-2-activated TIL clones irrespective of phenotype.
Furthermore, these data demonstrate that the effect of IL-4
was synergistic, not additive.
Blocking assay by IL-2 receptor
In order to clarify the mechanism of augmentation of
proliferation by IL-4, blocking assays using anti-IL-2
receptor a chain and / chain antibody were performed.
Data of representative TIL clones are shown in Table II.
Proliferation of the 1F7, CD4+ clone, was increased from
15.3 x 103 c.p.m. to 32.1 x 103 c.p.m. by IL-4. Neither the
anti-IL-2 receptor a chain antibody or the ,B chain antibody
alone inhibited proliferation. However, the simultaneous
addition of the ac chain and # chain antibody inhibited the
proliferation to the level of background (which was
3344+1850 c.p.m.), induced by IL-2 alone as well as IL-4
plus IL-2. Interestingly, the baseline level of inhibition
produced by the IL-2 receptor antibody was similar between
IL-2 alone and IL-4 combined with IL-2. The same results
were obtained with the TIL clone, 2F4 and 2DI0. These data
suggest that IL-4 augmentation of IL-2-induced proliferation
operates through an IL-2 pathway.
IL-2 binding assay and Scatchard analysis
In order to reveal the mechanism of IL-4 in terms of the IL-
2/IL-2 receptor system, IL-2 binding assays and Scatchard
analysis were performed on the representative TIL clone,
2D10 (Figure 2). The Kd of the high- and low-affinity IL-2
receptor of this clone was 200 pM and 2.8 nM respectively.
IL-4 increased the amount of IL-2 bound to the high-affinity
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Figure 1 TIL clone established by IL-2+IL-4. CD4+, CD8+ and CD4+CD8+ (double-positive) clones were obtained. All TIL
clones were CD3+, TCRa/f, and CD16-.
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Table I Effect of IL-4 on the proliferation of TIL clones
[3H]-TdR incorporation (c.p.m. x 103)
Phenotype Clone Medium IL-4 IL-2 IL-2+IL-4
CD4 1E5 0.3 0.7 2.1 7.3
1F7 0.3 2.6 15.3 32.1
2F4 0.5 2.4 10.0 27.8
3B8 0.2 5.9 1.0 8.4
CD8 1E4 0.7 1.3 34.5 43.3
2F7 0.7 0.9 7.1 13.4
2F8 0.4 0.9 5.1 8.2
3B9 NT NT 34.3 40.5
CD4.CD8 2D10 6.2 9.3 40.5 81.0
2E9 0.4 2.0 70.1 80.5
2F5 0.2 0.4 50.0 70.5
At clonal level, IL-4 augmented the proliferation ofevery phenotype ofclones. Representative data are shown.
Table II Blocking assay by anti-IL-2 receptor Ab
In vitro Blocking site (x 103, c.p.m.)
TIL clone treatment Control Ab a chain 3 chain oc chain+,B chain
1F7 IL-2 15.3 15.0 14.8 5.2
IL-2+IL-4 32.1 31.8 31.5 7.4
2F4 IL-2 10.0 9.8 9.7 3.5
IL-2+IL-4 27.8 26.2 25.8 9.0
2D10 IL-2 40.5 36.3 36.6 14.0
IL-2+IL-4 81.0 80.3 79.9 19.5
Blocking assay by IL-2 receptor a- and/or /3-chain Ab was performed. Simultaneous use of both Abs inhibited the proliferation of clones
stimulated with IL-2 and IL-4. Data ofthe reDresentative TIL clone are shown.
IL-2 receptor from 12 500 to 15 500 molecules per cell.
Similarly, IL-4 increased IL-2 binding to the low-affinity IL-2
receptor from 49000 to 67000 IL-2 molecules per cell.
However, IL-4 did not change the slope of the high- or low-
affinity IL-2 receptor binding curves.
Internalisation of IL-2
To analyse the binding of IL-2 to the TIL clones further,
internalisation of IL-2 was studied. Data of representative
TIL clones are shown in Table III. At early time points (10
and 30 min) following incubation with IL-4, the internalisa-
tion of IL-2 was enhanced as compared with incubation with
IL-2 alone. However, at later time points (60 and 120 min) of
incubation, there was no difference between IL-2 alone and
IL-2 plus IL-4 in the amount of IL-2 internalised. Moreover,
after incubation with IL-4 for only 10 min, over 75% of the
IL-2 was internalised. This demonstrates that IL-4 augments
the internalisation of IL-2 at an early phase.
Discussion
It has been reported that IL-4 augments the specific cytotoxic
activity against autologous melanoma cells and other types of
tumour cells (Kawakami et al., 1988, 1993). We have already
demonstrated that IL-4 accelerates the proliferation of IL-2-
activated TILs without altering the cytotoxic activity against
autologous adenocarcinoma cells, and IL-4 does not alter the
phenotypes of TILs (Tsunoda et al., 1992). However, the
mechanism of IL-4 has remained unclear. In order to clarify
the mechanism of IL-4, we first established clones of TILs.
CD4+, CD8+ and CD4+CD8+ (double positive) T-cell clones
were established from freshly isolated TILs. About 3% of T
cells in peripheral blood are double-positive T cells (Blue et
al., 1985). Double-positive T cells are thought to be an
intermediate phenotype between immature double-negative T
cells and mature single-positive (CD4 or CD8) T cells during
the differentiation of T cells in the thymus (McPhee et al.,
1979; Penit, 1986). Our studies (Yamaue et al., 1990) and
those of others (Whiteside et al., 1986; Ebert et al., 1989;
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Figure 2 Binding assay and Scatchard analysis of TIL clone
stimulated with IL-4. IL-4 up-regulated the low- and high-affinity
IL-2 receptors without altering the slope of either receptor.
Results were obtained using the representative TIL clone, 2DI0.
Shimizu et al., 1990; Whitford et al., 1990; Viale et al., 1990)
have not observed a subpopulation of double-positive T cells
in TILs. In our system, IL-4 was used to establish TIL clones
and it was thought that IL-4 augments the expression of the
CD8 molecule in CD4+ T cells (Paliard et al., 1988). This
might be the reason why we could establish double-positive
T-cell clones.
The cytokine production of these TIL clones was
measured. IL-I, IFN-y and TNFcx were produced from these
TIL clones (data not shown). It may be indicated that IL-4
augments the cytokine network system (Lorre et al., 1990).
Next, by using three different T-cell clones, proliferationIL-4 augments TIL via IL-2 receptor
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Table III Internalisation of IL-2 molecule in TIL clones incubated with IL-4
In vitro Time course (min) of[125IIIL-2 ( x 103c.p.m.)
TIL clone treatment 0 10 30 60 120
IF7 IL-2 2.7 4.1 4.5 7.2 8.1
IL-2 +IL-4 2.8 6.9 7.1 7.7 9.3
2F4 IL-2 2.5 3.4 3.3 5.2 6.1
IL-2 +IL-4 2.5 6.4 6.8 5.6 7.2
2D10 IL-2 4.2 5.0 6.0 9.5 11.2
IL-2+IL-4 4.2 8.1 9.3 9.9 12.0
IL-4 augmented the internalisation of IL-2 during the early phase (10 and 30min). Over 75% ofinternalisation was acheived by
30min. Representative data were shown. The value oftime 0 means the background proliferation.
induced by IL-4 and/or IL-2 was measured. IL-4 alone
augmented proliferation of TIL clones irrespective of
phenotype, and furthermore, IL-4 combined with IL-2
enhanced the proliferation of every TIL clone in comparison
with IL-2 alone. These results indicate two important points.
First, IL-4 augments the proliferation of TILs at the clonal
level independent of their phenotype. Second, the augmenta-
tion of IL-4 combined with IL-2 is synergistic. In the present
report, we focused on the mechanism by which IL-4
enhanced the proliferation induced with IL-2. In this
mechanism, IL-2 and IL-2 receptor system were thought to
be crucial (Fernandez-Botran et al., 1989; Kawakami et al.,
1989; Ishikawa et al., 1991). In our studies, a blocking assay
using anti-IL-2 receptor x-chain antibody (CD25) and /3-
chain antibody (TU27) was performed on representative
clones. IL-2 receptor oc chain alone (low affinity) and /B chain
alone (intermediate) did not inhibit proliferation in compar-
ison with control antibody. However, simultaneous addition
of both IL-2 receptor antibodies inhibited proliferation.
Interestingly, the inhibition was similar in clones cultured
with IL-2 alone or with IL-2 plus IL-4. It is suggested that
the augmentation of IL-4 is related to high-affinity IL-2
receptor. However, cell surface expression of IL-2 receptor a-
chain, /3-chain and IL-4 receptor by these clones was analysed
by flow cytometry. There was no difference in receptor
expression between cells stimulated with IL-2 alone or IL-2
plus IL-4 (data not shown).
Furthermore, the IL-2 binding assay and Scatchard
analysis at clonal level showed that IL-4 did not change the
value of Kd of the high-affinity IL-2 receptor (200 pM) and
the low-affinity IL-2 receptor (2.8 nM) in comparison with IL-
2 alone. These data suggest that IL-4 does not change the
functional characteristics of the IL-2 receptor. On the other
hand, IL-4 increased the binding amount of IL-2 molecule on
the cell surface at both the IL-2 receptors. It is especially
important that IL-4 increases the binding of IL-2 on the
high-affinity IL-2 receptor, since this receptor is thought to be
related to signal transduction (Yagita et al., 1989). This may
be the mechanism for the synergistic effect of IL-4 on
proliferation.
The increase of binding IL-2 molecule on TILs exposed to
IL-4 prompted us to examine the internalisation of IL-2,
which depends on the latter receptor (Fujii et al., 1986; Siegel
et al., 1987; Robb et al., 1987; Yoshimoto et al., 1990). It was
found that internalisation of IL-2 was augmented by IL-4 at
the early incubation time points (10 and 30 min). Thus, the
enhanced internalisation of IL-2 induced by IL-4 may
accelerate delivery signals of transduction that is followed
by the heightened proliferation of TILs. The combined effects
that IL-4 has on up-regulation of the high-affinity IL-2
receptor, increasing the amount of IL-2 bound per TIL, and
enhancement of internalisation of IL-2 together lead to
augmentation of TIL proliferation.
Recently, IL-2 receptor y chain has been sequenced and
analysed in detail (Takeshita et al., 1992). High-affinity IL-2
receptor was clarified to consist of a-, f,- and y-chain, and the
y-chain was shown to be crucial to signal transduction
(Nakamura et al., 1993). Moreover, the IL-2 receptor y-chain
has high homology to the IL-4 receptor (Kondo et al., 1993).
IL-2 receptor y-chain may play an important role in the
augmentation of TIL proliferation caused by IL-4. We have
shown at the clonal level that IL-4 augmented the
proliferation of TIL clones via the IL-2 receptor. At
present, we are now attempting to analyse the involvement
ofthe IL-2 receptor y-chain in the stimulation ofproliferation
produced by IL-4.
The expression of IL-4 receptor was analysed by radio-
immunoassay. There was no significant difference by
stimulation with IL-4 (data not shown). However, it is
possible that the phenomena reported reflect some inside-out
modulation of surface IL-2 receptor mediated via the IL-4/
IL-4 receptor system.
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